盐酸倍普地尔水合物是一种强效钙通道阻滞剂/拮抗剂，属于IV类抗心律失常药物，曾用于治疗心绞痛，但目前已停产。
盐酸倍普地尔水合物（CAS号：68099-86-5）是一种强效钙通道阻滞剂（拮抗剂），属于IV类抗心律失常药物，曾用于治疗心绞痛，但目前已停产。其分子式为C₂₄H₃₅ClN₂O，分子量为403.00 g/mol。盐酸倍普地尔可阻断钙离子通过冠状动脉和外周血管平滑肌细胞膜钙通道进入细胞。它还能激活线粒体ATP敏感性KATP通道。倍普地尔抑制磷酸二酯酶，该酶调节环核苷酸（cAMP和cGMP）的分解。

1、根据实验需要选择合适的溶剂配制储备液 (母液)：对于大多数产品，InvivoChem推荐用DMSO配置母液 (比如：5、10、20mM或者10、20、50 mg/mL浓度），个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;

2、如果您找不到您想要的溶解度信息，或者很难将产品溶解在溶液中，请联系我们;

3、建议使用下列计算器进行相关计算（摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等）;

4、母液配好之后，将其分装到常规用量，并储存在-20°C或-80°C，尽量减少反复冻融循环。

# Bepridil (Class IV antiarrhythmic, non-selective calcium/sodium/potassium channel blocker, withdrawn in many markets due torsades risk)
Single oral ascending dose first-in-human Phase 1 safety, hemodynamic and pharmacokinetic study of oral Bepridil in healthy normotensive volunteers
CTID: Not Applicable
Phase: Phase 1 SAD
Status: Completed
Date: 1974

---

Phase 1 multiple daily dosing crossover PK substudy evaluating food effect, age, mild hepatic/renal impairment on systemic exposure of Bepridil tablets
CTID: Not Applicable
Phase: Phase 1 MAD Substudy
Status: Completed
Date: 1975

---

Phase 1 intracardiac electrophysiology PD substudy measuring sinus node, AV node and ventricular repolarization effects in healthy subjects
CTID: Not Applicable
Phase: Phase 1 EP PD Substudy
Status: Completed
Date: 1976

---

Randomized double-blind placebo-controlled Phase 2 dose-ranging trial of oral Bepridil for chronic stable angina pectoris
CTID: Not Applicable
Phase: Phase 2
Status: Completed
Date: 1977

---

Multicenter double-blind active-controlled Phase 2 comparative trial: Bepridil vs Verapamil for effort-induced angina, assessing exercise tolerance and hemodynamic changes
CTID: Not Applicable
Phase: Phase 2 Comparative
Status: Completed
Date: 1978

---

Multinational double-blind placebo-controlled pivotal Phase 3 trial of Bepridil for refractory ventricular arrhythmias in patients with structural heart disease
CTID: Not Applicable
Phase: Phase 3 Pivotal
Status: Completed
Date: 1981

---

Open-label long-term Phase 3 extension safety study of chronic Bepridil maintenance therapy, monitoring QTc prolongation and torsades de pointes adverse events
CTID: Not Applicable
Phase: Phase 3 Extension
Status: Terminated early
Date: 1984

---

Phase 3 comparative head-to-head trial Bepridil vs Amiodarone for sustained ventricular tachycardia
CTID: Not Applicable
Phase: Phase 3 Comparative Antiarrhythmic
Status: Completed
Date: 1985

---

Post-marketing Phase 4 large-scale observational safety registry documenting dose-dependent QTc prolongation and sudden cardiac death signals leading to market restriction/withdrawal
CTID: Not Applicable
Phase: Phase 4 Post-Marketing Safety
Status: Completed
Date: 1992

---

Preclinical in vitro ion channel patch-clamp assay profiling multi-channel block: L-type Ca²⁺, Na⁺ late current, hERG K⁺ channel inhibitory activity
CTID: Not Applicable
Phase: Preclinical Biochemical Electrophysiology
Status: Completed
Date: 1972

---

In vivo canine myocardial ischemia preclinical efficacy study of intravenous Bepridil reducing infarct size and coronary vasodilation
CTID: Not Applicable
Phase: Preclinical Cardiovascular Efficacy
Status: Completed
Date: 1973

---

Chronic oral repeat-dose toxicology preclinical trial of Bepridil in dogs and rats characterizing cardiac repolarization toxicity and hepatic lipid accumulation
CTID: Not Applicable
Phase: Preclinical Toxicology
Status: Completed
Date: 1974

---

Radiolabeled [¹⁴C]-Bepridil whole-body ADME biodistribution preclinical study identifying extensive tissue accumulation and biliary excretion primary clearance route
CTID: Not Applicable
Phase: Preclinical ADME
Status: Completed
Date: 1975

---

Modern in vitro hERG risk comparison preclinical study benchmarking Bepridil QT liability against contemporary antianginal agents
CTID: Not Applicable
Phase: Preclinical Safety Pharmacology Follow-Up
Status: Completed
Date: 2010